Your browser doesn't support javascript.
loading
Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013.
Head, Michael G; Fitchett, Joseph R; Nageshwaran, Vaitehi; Kumari, Nina; Hayward, Andrew; Atun, Rifat.
Afiliação
  • Head MG; University College London, Farr Institute for Health Informatics, 222 Euston Road, London NW1 2DA, United Kingdom; Academic Unit of Clinical and Experimental Sciences Faculty of Medicine, University of Southampton, United Kingdom. Electronic address: m.head@ucl.ac.uk.
  • Fitchett JR; London School of Hygiene & Tropical Medicine, Keppel Street, London, United Kingdom; Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Nageshwaran V; Imperial College London, School of Medicine, London, United Kingdom.
  • Kumari N; Imperial College London, School of Medicine, London, United Kingdom.
  • Hayward A; University College London, Farr Institute for Health Informatics, 222 Euston Road, London NW1 2DA, United Kingdom.
  • Atun R; Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA.
EBioMedicine ; 3: 180-190, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26870829
ABSTRACT

BACKGROUND:

Infectious diseases account for a significant global burden of disease and substantial investment in research and development. This paper presents a systematic assessment of research investments awarded to UK institutions and global health metrics assessing disease burden.

METHODS:

We systematically sourced research funding data awarded from public and philanthropic organisations between 1997 and 2013. We screened awards for relevance to infection and categorised data by type of science, disease area and specific pathogen. Investments were compared with mortality, disability-adjusted life years (DALYs) and years lived with disability (YLD) across three time points.

FINDINGS:

Between 1997-2013, there were 7398 awards with a total investment of £3.7 billion. An increase in research funding across 2011-2013 was observed for most disease areas, with notable exceptions being sexually transmitted infections and sepsis research where funding decreased. Most funding remains for pre-clinical research (£2.2 billion, 59.4%). Relative to global mortality, DALYs and YLDs, acute hepatitis C, leishmaniasis and African trypanosomiasis received comparatively high levels of funding. Pneumonia, shigellosis, pertussis, cholera and syphilis were poorly funded across all health metrics. Tuberculosis (TB) consistently attracts relatively less funding than HIV and malaria.

INTERPRETATION:

Most infections have received increases in research investment, alongside decreases in global burden of disease in 2013. The UK demonstrates research strengths in some neglected tropical diseases such as African trypanosomiasis and leishmaniasis, but syphilis, cholera, shigellosis and pneumonia remain poorly funded relative to their global burden. Acute hepatitis C appears well funded but the figures do not adequately take into account projected future chronic burdens for this condition. These findings can help to inform global policymakers on resource allocation for research investment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pesquisa / Saúde Global / Investimentos em Saúde Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pesquisa / Saúde Global / Investimentos em Saúde Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article